Search results
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal, says report - CNBC TV18
CNBC TV18· 6 days agoLilly counts its IBD drug, Omvoh, among its future growth drivers, besides its blockbuster weight...
Lilly counts its IBD drug, Omvoh, among its future growth drivers, besides its blockbuster weight...